Table 1. Demographic and baseline characteristics of 152 elderly patients with AML.
| Characteristic | Value |
| Age, year (median, range) | 68, 60–94 |
| 60–69 years, n (%) | 93(61.2) |
| 70–79 years, n (%) | 49(32.2) |
| >80 years, n (%) | 10(6.6) |
| Male gender, n (%) | 91(59.9) |
| Previous hematologic diseases, n (%) | 20(13.2) |
| MDS | 14(9.2) |
| CMML | 2(1.3) |
| ITP | 1(0.7) |
| PV | 1(0.7) |
| IMF | 1(0.7) |
| NHL | 1(0.7) |
| Previous tumors of other systems, n (%) | 8(5.3) |
| Extramedullary presentation, n (%) | 39(25.7) |
| WBC at diagnosis, ×109/L (median, range) # | 7.60, 0.41–272.3 |
| ≤ 30, n (%) | 105(69.5) |
| Hemoglobin at diagnosis, g/L (median, range) # | 76.0, 34.0–131.0 |
| Normal (male 120–160, female 110–150), n (%) | 5(3.3) |
| Anemia (male < 120, female < 110), n (%) | 146(96.7) |
| Platelet at diagnosis, ×109/L (median, range) # | 46.0, 2.0–463.0 |
| Normal (100–300), n (%) | 25(16.6) |
| Thrombocytopenia (< 100), n (%) | 124(82.1) |
| Thrombocythemia (> 300), n (%) | 2(1.3) |
| Missing data, n | 1 |
| LDH at diagnosis, U/L (median, range) $ | 329, 92–2899 |
| ≤ 250 U/L, n (%) | 46(32.2) |
| > 250 U/L, ≤ 1000 U/L, n (%) | 79(55.2) |
| > 1,000 U/L, n (%) | 18(12.6) |
| BM blasts at diagnosis, % (median, range) & | 59.0, 20.0–96.2 |
| ≥ 20%, ≤ 50%, n (%) | 62(41.6) |
| > 50%, ≤ 80%, n (%) | 49(32.9) |
| > 80%, n (%) | 38(25.5) |
| FAB subtype, n (%) | |
| M0 | 6(3.9) |
| M1 | 24(15.8) |
| M2 | 73(48.0) |
| M4 | 15(9.9) |
| M5 | 18(11.8) |
| M6 | 10(6.6) |
| M7 | 2(1.3) |
| Unclassified | 4(2.6) |
| FLT3-ITD mutation status, mutated +/total (%) | 7/72(9.7) |
| NPM1 mutation status, mutated +/total (%) | 16/67(23.9) |
| CEBPα mutation status, mutated +/total (%)* | 10/62(16.1) |
| Cytogenetics, n (%) | |
| Favorable | 5(4.6) |
| Intermediate | 92(85.2) |
| Unfavorable | 11(10.2) |
AML, acute myeloid leukemia; MDS: myelodysplastic syndromes; CMML: Chronic myelomonocytic leukemia; ITP: Idiopathic thrombocytopenic purpura; PV: polycythemia vera; IMF: idiopathic myelofibrosis; NHL: non-Hodgkin's lymphoma; WBC: white blood cell, normal range: 4–10×109/L; LDH: lactate dehydrogenase, normal range: 110–250 U/L; BM: bone marrow; FAB: the French American British; FLT3-ITD: internal tandem duplications of FMS-like tyrosine kinase-3; NPM1: nucleophosmin 1; CEBPα: CCAAT/enhancer-binding protein alpha; Missing data: # n = 1; $ n = 9; & n = 3; * n = 44.